These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15290663)

  • 1. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer.
    Osterlund P; Ruotsalainen T; Peuhkuri K; Korpela R; Ollus A; Ikonen M; Joensuu H; Elomaa I
    Clin Gastroenterol Hepatol; 2004 Aug; 2(8):696-703. PubMed ID: 15290663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.
    Holma R; Laatikainen R; Orell H; Joensuu H; Peuhkuri K; Poussa T; Korpela R; Österlund P
    Nutrients; 2020 Feb; 12(2):. PubMed ID: 32033152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.
    Osterlund P; Ruotsalainen T; Korpela R; Saxelin M; Ollus A; Valta P; Kouri M; Elomaa I; Joensuu H
    Br J Cancer; 2007 Oct; 97(8):1028-34. PubMed ID: 17895895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
    Holma R; Korpela R; Sairanen U; Blom M; Rautio M; Poussa T; Saxelin M; Osterlund P
    J Clin Gastroenterol; 2013 Jan; 47(1):45-51. PubMed ID: 23090038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Ward S; Kaltenthaler E; Cowan J; Brewer N
    Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial.
    Pakdaman MN; Udani JK; Molina JP; Shahani M
    Nutr J; 2016 May; 15(1):56. PubMed ID: 27207411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NONINVASIVE BREATH TESTS FOR DIAGNOSIS OF SIBO AND LACTOSE INTOLERANCE IN PATIENTS ON CHEMOTHERAPY TREATMENT FOR COLORECTAL AND GASTRIC CÂNCER.
    Gonçalves AR; Ambrogini O; Forones NM
    Arq Gastroenterol; 2021; 58(1):26-31. PubMed ID: 33909793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
    Zaniboni A
    J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
    Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced colorectal cancer: quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil.
    Bogliolo G; Pannacciulli I; Desalvo L; Barsotti B; Lerza R; Mencoboni M; Arboscello E
    Anticancer Res; 2000; 20(1B):501-4. PubMed ID: 10769713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
    Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
    J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
    Conti JA; Kemeny NE; Saltz LB; André AM; Grossano DD; Bertino JR
    Cancer; 1995 Feb; 75(3):769-74. PubMed ID: 7828126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
    Popov IP; Jelic SB; Matijasevic MM; Grbic B; Babic DR
    J Exp Clin Cancer Res; 2004 Sep; 23(3):395-401. PubMed ID: 15595627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced lactose intolerance in adults.
    Parnes HL; Fung E; Schiffer CA
    Cancer; 1994 Sep; 74(5):1629-33. PubMed ID: 8062196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.